FTC pulls its OptumRx insulin pricing case to review a final settlement

The Federal Trade Commission withdrew its in-house case against OptumRx from adjudication so it could review a final settlement, Law360 reported on June 15, 2026. The case accuses pharmacy benefit managers of using rebate schemes that inflated insulin list prices. Law360 described the deal as the third and final settlement in the case, with terms not disclosed in its reporting.

• FTC withdrew the in-house case against OptumRx from adjudication to review the final deal
• The case alleges PBM rebate practices inflated insulin list prices
• Law360 calls it the third and final settlement in the case
• Settlement terms were not disclosed in the reporting